Biologic agents.
... this newer class of DMARDs includes
abatacept (Orencia),
adalimumab (Humira),
anakinra (Kineret),
certolizumab (Cimzia),
etanercept (Enbrel),
golimumab (Simponi),
infliximab (Remicade),
rituximab (Rituxan),
tocilizumab (Actemra)
tofacitinib (Xeljanz).
These drugs can target parts of the immune system that trigger inflammation that causes joint and tissue damage. These types of drugs also increase the risk of infections.
|